Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at UBS Group from $30.00 to $34.00 ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $40.00 target ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Exelixis Inc. has synthesized fused pyrazole derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of ...